KR20020012221A - 체액성 및 세포성 면역 반응을 증진시키기 위한, 안정성과생체 적합성이 최적화된 애쥬반트 - Google Patents

체액성 및 세포성 면역 반응을 증진시키기 위한, 안정성과생체 적합성이 최적화된 애쥬반트 Download PDF

Info

Publication number
KR20020012221A
KR20020012221A KR1020017014653A KR20017014653A KR20020012221A KR 20020012221 A KR20020012221 A KR 20020012221A KR 1020017014653 A KR1020017014653 A KR 1020017014653A KR 20017014653 A KR20017014653 A KR 20017014653A KR 20020012221 A KR20020012221 A KR 20020012221A
Authority
KR
South Korea
Prior art keywords
sba
lipid
adjuvant
particles
oil
Prior art date
Application number
KR1020017014653A
Other languages
English (en)
Korean (ko)
Inventor
레이너 헬무트 뮐러
니콜라스 그루호퍼
카스텐 올브리치
Original Assignee
파르마솔 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 파르마솔 게엠베하 filed Critical 파르마솔 게엠베하
Publication of KR20020012221A publication Critical patent/KR20020012221A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
KR1020017014653A 1999-05-20 2000-05-19 체액성 및 세포성 면역 반응을 증진시키기 위한, 안정성과생체 적합성이 최적화된 애쥬반트 KR20020012221A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19923256.3 1999-05-20
DE19923256 1999-05-20
PCT/EP2000/004565 WO2000071154A2 (de) 1999-05-20 2000-05-19 Stabilitäts-, biokompatibilitäts-optimiertes adjuvans (sba) zur erhöhung der humoralen und zellulären immunantwort

Publications (1)

Publication Number Publication Date
KR20020012221A true KR20020012221A (ko) 2002-02-15

Family

ID=7908697

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017014653A KR20020012221A (ko) 1999-05-20 2000-05-19 체액성 및 세포성 면역 반응을 증진시키기 위한, 안정성과생체 적합성이 최적화된 애쥬반트

Country Status (11)

Country Link
EP (1) EP1183045A2 (tr)
JP (1) JP2003500365A (tr)
KR (1) KR20020012221A (tr)
AU (2) AU5214200A (tr)
BR (1) BR0010823A (tr)
CA (1) CA2373239A1 (tr)
DE (1) DE10024788A1 (tr)
MX (1) MXPA01011660A (tr)
TR (1) TR200103333T2 (tr)
WO (2) WO2000071154A2 (tr)
ZA (1) ZA200109147B (tr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140026638A (ko) * 2005-09-14 2014-03-05 맨카인드 코포레이션 활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10024788A1 (de) * 1999-05-20 2000-11-23 Gerbu Gmbh Stabilitäts-, Biokompatibilitäts-optimiertes Adjuvans (SBA) zur Erhöhung der humoralen und zellulären Immunantwort
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
ES2300568T3 (es) 2002-03-20 2008-06-16 Mannkind Corporation Aparato de inhalacion.
ES2379267T3 (es) * 2003-10-23 2012-04-24 Novartis Vaccines And Diagnostics, Inc. Composiciones estabilizadas
FR2873386B1 (fr) 2004-07-22 2011-01-14 Agence Francaise De Securite Sanitaire Des Aliments Afssa Composition vaccinale contre le rhodococcus equi
CA2575692C (en) 2004-08-20 2014-10-14 Mannkind Corporation Catalysis of diketopiperazine synthesis
KR20130066695A (ko) 2004-08-23 2013-06-20 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
MX2008010721A (es) 2006-02-22 2008-09-01 Mannkind Corp Un metodo para mejorar las propiedades farmaceuticas de microparticulas que contienen dicetopiperazina y un agente activo.
US8424518B2 (en) 2008-06-13 2013-04-23 Mannkind Corporation Dry powder inhaler and system for drug delivery
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
EP2609954B1 (en) 2008-06-20 2021-12-29 MannKind Corporation An interactive apparatus for real-time profiling of inhalation efforts
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
JP5667095B2 (ja) 2009-03-11 2015-02-12 マンカインド コーポレイション 吸入器の抵抗を測定するための装置、システムおよび方法
KR20180036807A (ko) 2009-06-12 2018-04-09 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
CA2801936C (en) 2010-06-21 2021-06-01 Mannkind Corporation Dry powder drug delivery system and methods
CN103826988B (zh) 2011-04-01 2016-03-09 曼金德公司 用于药物药盒的泡罩包装
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
AU2012328885B2 (en) 2011-10-24 2017-08-31 Mannkind Corporation Methods and compositions for treating pain
AU2013256565B2 (en) 2012-04-30 2015-12-03 Ossur Hf Prosthetic device, system and method for increasing vacuum attachment
AU2013289957B2 (en) 2012-07-12 2017-02-23 Mannkind Corporation Dry powder drug delivery systems and methods
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
CA2906817C (en) 2013-03-15 2022-01-18 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
MX2016000739A (es) 2013-07-18 2017-04-06 Mannkind Corp Composiciones farmacéuticas en polvo seco estables al calor y métodos.
CA2920488C (en) 2013-08-05 2022-04-26 Mannkind Corporation Insufflation apparatus and methods
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
US20180318415A1 (en) * 2015-12-08 2018-11-08 Glaxosmithkline Biologicals, Sa Novel adjuvant formulations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19745950A1 (de) * 1997-10-17 1999-04-22 Dds Drug Delivery Service Ges Arzneistoffträgerpartikel für die gewebespezifische Arzneistoffapplikation
WO2000006120A1 (en) * 1998-07-31 2000-02-10 Korea Institute Of Science And Technology Lipid emulsion and solid lipid nanoparticle as a gene or drug carrier
DE10024788A1 (de) * 1999-05-20 2000-11-23 Gerbu Gmbh Stabilitäts-, Biokompatibilitäts-optimiertes Adjuvans (SBA) zur Erhöhung der humoralen und zellulären Immunantwort

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140026638A (ko) * 2005-09-14 2014-03-05 맨카인드 코포레이션 활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법

Also Published As

Publication number Publication date
ZA200109147B (en) 2002-05-08
AU5214200A (en) 2000-12-12
CA2373239A1 (en) 2000-11-30
BR0010823A (pt) 2002-03-05
AU5809100A (en) 2000-12-12
EP1183045A2 (de) 2002-03-06
WO2000071154A2 (de) 2000-11-30
WO2000071154A3 (de) 2001-06-28
DE10024788A1 (de) 2000-11-23
TR200103333T2 (tr) 2002-04-22
WO2000071077A2 (en) 2000-11-30
MXPA01011660A (es) 2004-04-05
JP2003500365A (ja) 2003-01-07

Similar Documents

Publication Publication Date Title
KR20020012221A (ko) 체액성 및 세포성 면역 반응을 증진시키기 위한, 안정성과생체 적합성이 최적화된 애쥬반트
JP6625587B2 (ja) Ｔｌｒ２を活性化するか、またはその活性を増加させるアジュバントを含むリポソーム組成物およびその使用
Mohammed et al. Lyophilisation and sterilisation of liposomal vaccines to produce stable and sterile products
Christensen et al. Liposome-based cationic adjuvant formulations (CAF): past, present, and future
ES2258108T3 (es) Vacunas con respuesta inmune mejorada y procedimientos de preparacion de las mismas.
US8277823B2 (en) Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids
EP1765289B1 (en) Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids
Liu et al. Cubosome nanoparticles potentiate immune properties of immunostimulants
JP2014528955A5 (tr)
AU2008307042B2 (en) Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
KR100726818B1 (ko) 오일 면역 보강제 백신
ES2924988T3 (es) Composiciones con nanoemulsiones para prevenir, inhibir o eliminar una enfermedad alérgica e inflamatoria
Bobbala et al. Novel injectable pentablock copolymer based thermoresponsive hydrogels for sustained release vaccines
JPH06504759A (ja) リポソーム含有ワクチン組成物
US20200405846A1 (en) Emulsion adjuvant for intramuscular, intradermal and subcutaneous administration
Perrie et al. Recent developments in particulate-based vaccines
US20100209452A1 (en) Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
ES2234152T3 (es) Vectores de antigenos en forma de vesiculas multilamelares.
US20220257753A1 (en) Vaccine Adjuvants for Antigen Delivery
Patel et al. Cationic nanoparticles for delivery of CpG oligodeoxynucleotide and ovalbumin: In vitro and in vivo assessment
Kirby Formulation and characterisation of an effective particulate delivery vehicle for the novel sub-unit vaccine antigen, Ag85B-ESAT-6
Christensen et al. Liposomes in adjuvant systems for parenteral delivery of vaccines
Hoseinjani et al. Evaluation of infection course in mice induced by L. major in presence of positively charged liposomes containing CpG ODN
Demana ISCOMs and related colloidal particles prepared by the lipid film hydration method for antigen delivery

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid